Kyriakos Stavridis

Dr. Kyriakos Stavridis

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2015 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
NMNikolaos Melas
Nikolaos Melas
KSKyriakos Stavridis
Kyriakos Stavridis
ASAthanasios Saratzis
Athanasios Saratzis
JLJohn Lazarides
John Lazarides
CGChristos Gitas
Christos Gitas
NSNikolaos Saratzis
Nikolaos Saratzis
Purpose: To investigate the performance of a new device that uses the STRATA polytetrafluoroethylene graft material and a mechanism that provides active proximal sealing in order to prevent type Ia endoleak during endovascular aneurysm repair (EVAR). Methods: Between April 2013 and July 2014, 21 consecutive patients (all men; median age 71 years, range 60–84 years) with abdominal aortic aneurysm (median diameter 5.9 cm, range 4.9–7.8 cm) and suitable anatomy were offered elective EVAR using the AFX endograft. These patients had an irregular, conical, tapered, or bulging proximal neck, for which this specific device was considered appropriate. Aneurysm exclusion and incidence of type Ia endoleak were the primary outcomes; secondary outcomes included mortality, morbidity, migration, and other graft-related complications. Results: Primary technical success was 90%; 2 intraoperative type Ia endoleaks due to low endograft deployment were treated with additional proximal cuffs. During a median follow-up of 10 months (range 2–15 months), no type I endoleak was observed. One type II endoleak was encountered, with no associated sac enlargement. There was no stent-graft migration or any other device-related complication. One patient had a nonfatal myocardial infarction and another developed renal failure requiring transient dialysis. No deaths occurred. Conclusion: In this early experience, this newly available device appears to be safe and efficient in providing seal along irregularly shaped necks over the short term.

8 February 2024 in Medicina
Verified
Journal Article
Open access
PDF file
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
SNSpyridon Nikas
Spyridon Nikas
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
KSKaterina Sidiropoulou
Katerina Sidiropoulou
KSKyriakos Stavridis
Kyriakos Stavridis
NSNikolaos Saratzis
Nikolaos Saratzis
Background: Prospective single and multicenter studies have shown improved outcomes of patients who underwent carotid artery stenting with the novel CGuard dual-layer mesh stent at 1 year. Objectives: The aim of this study is to conduct a systematic review and meta-analysis of all published studies to assess 1-year efficacy and outcomes of CGuard in patients with carotid stenting. Methods: A systematic search was performed. All studies enrolling at least 20 patients were included in our analysis. The primary endpoints were death (all-cause, cardiovascular and ipsilateral stroke-related death) and stroke rate at 1 year. The secondary endpoint was in-stent restenosis at 1 year. Results: The final analysis included 1709 patients. The one-year all-cause mortality rate was 2.97% (39/1699, 95% CI: 1.26–6.86%, I2 = 67%, t2 = 0.3442, p < 0.01), cardiovascular-related death was 0.92% (10/1616, 95% CI: 0.35–2.39%, I2 = 34%, t2 = 0.2302, p = 0.18), and ipsilateral stroke-related death was 0.3% (1/1649, 95% CI: 0.1–0.87%, I2 = 0%, t2 = 0, p = 0.69). The one-year ipsilateral stroke rate was 1.21% (16/1649, 95% CI: 0.58–2.5%, I2 = 28%, t2 = 0.1433, p = 0.23), transient ischemic attacks (TIAs) rate was 1.78% (19/1149, 95% CI: 1.11–2.84%, I2 = 0%, t2 = 0, p = 0.69), and total composite 1-year stroke/TIA rate was 2.97% (32/1149, 95% CI: 1.84–4.77%, I2 = 0%, t2 = 0, p = 0.41). The in-stent restenosis rate at 1 year was 1.06% (13/1653, 95% CI: 0.48–2.34%, I2 = 28%, t2 = 0.2308, p = 0.22). Conclusions: This meta-analysis shows that CAS with CGuard is safe with minimal neurological adverse events and in-stent restenosis rate at 1 year.

18 November 2015 in Blood Pressure
Verified
Journal Article
Closed access
PDF file
Pantelis A SarafidisPantelis A Sarafidis
Pantelis A Sarafidis
KSKyriakos Stavridis
Kyriakos Stavridis
Charalampos LoutradisCharalampos Loutradis
Charalampos Loutradis
ASAthanasios N. Saratzis
Athanasios N. Saratzis
PPPanagiotis Pateinakis
Panagiotis Pateinakis
NSNicolaos Saratzis
Nicolaos Saratzis
To intervene or not? A man with multidrug-resistant hypertension, endovascular abdominal aneurysm repair, bilateral renal artery stenosis and end-stage renal disease salvaged with renal artery stenting. . ???aop.label???. doi: 10.3109/08037051.2015.1110926

31 December 2018 in Vascular Specialist International
Verified
Journal Article
Open access
FSFragiska Sigala
Fragiska Sigala
GGGeorge Galyfos
George Galyfos
KSKyriakos Stavridis
Kyriakos Stavridis
KTKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
ILIoannis Lazaridis
Ioannis Lazaridis
NSNikolaos Saratzis
Nikolaos Saratzis
Aim of this study is to report real-life experience on the treatment of peripheral artery disease (PAD) with a specific drug-coated balloon (DCB), and to evaluate potential prognostic factors for outcomes. This is a retrospective study reporting outcomes in patients with PAD who were treated with the Lutonix DCB during a four-year period. Major outcomes included: all-cause mortality, amputation, clinical improvement, wound healing and target lesion revascularization (TLR). Mean follow-up was 24.2±2.3 months. Overall, 149 patients (mean age: 68.6±8.3 years; 113 males) were treated, either for intermittent claudication (IC) (n=86) or critical limb ischemia (CLI) (n=63). More than half the target lesions (n=206 in total) were located in the superficial femoral artery and 18.0% were below-the-knee lesions. CLI patients presented more frequently with infrapopliteal (P=0.002) or multilevel disease (P=0.0004). Overall, all-cause mortality during follow-up was 10.7%, amputation-free survival was 81.2% and TLR-free survival was 96.6%. CLI patients showed higher all-cause mortality (P=0.007) and total amputation (P=0.0001) rates as well as lower clinical improvement (P=0.0002), compared to IC patients. Coronary artery disease (CAD), gangrene and infrapopliteal disease were found to be predictors for death whereas CLI and gangrene were found to be predictors for amputation, during follow-up. PAD treatment with Lutonix DCBs seems to be an efficient and safe endovascular strategy yielding promising results. However, CAD, gangrene, CLI and infrapopliteal lesions were found to be independent predictors for adverse outcomes. Larger series are needed to identify additional prognostic factors.

1 February 2019 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
DKDimitrios Karamanos
Dimitrios Karamanos
KSKyriakos Stavridis
Kyriakos Stavridis
NZNikolaos Zacharopoulos
Nikolaos Zacharopoulos
MTMarianthi Tympanidou
Marianthi Tympanidou
ILIoannis Lazaridis
Ioannis Lazaridis

27 November 2017 in Case Reports in Vascular Medicine
Verified
Journal Article
Open access
PDF file
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
KSKyriakos Stavridis
Kyriakos Stavridis
ILIoannis Lazaridis
Ioannis Lazaridis
NSNikolaos Saratzis
Nikolaos Saratzis
Aortobronchial fistula (ABF) is a rare condition which can be lethal if left untreated. Open surgical treatment carries high morbidity and mortality. Recent advances in endovascular technology have made thoracic endovascular aortic repair (TEVAR) the treatment of choice. We present a successful endovascular repair of aortobronchial fistula due to a saccular aneurysm of descending thoracic aorta.